Get started
Author

Shuyan Du

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
2018 · A. N. Niemeijer, D. Leung, et al. · Nature Communications · 485
PDF
Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
2020 · Laurent Dercle, Matthew Fronheiser, et al. · Clinical Cancer Research · 174
Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils
2016 · Todd G. Kirchgessner, Paul Sleph, et al. · Cell Metabolism · 170
PDF
Excessive Activation of Notch Signaling in Macrophages Promote Kidney Inflammation, Fibrosis, and Necroptosis
2022 · Tiankui Ma, Xin Li, et al. · Frontiers in Immunology · 116
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
2023 · Manal F. Abdelmalek, Arun J. Sanyal, et al. · Clinical Gastroenterology and Hepatology · 110
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
2023 · Rohit Loomba, Arun J. Sanyal, et al. · Clinical Gastroenterology and Hepatology · 110
PDF
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
2021 · Eric J. Lawitz, Diane E. Shevell, et al. · Hepatology · 107
PDF
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial
2015 · Hamed Emami, Esad Vucic, et al. · Atherosclerosis · 77
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease
2017 · Viktor Martyanov, Grace-Hyun J. Kim, et al. · PLoS ONE · 71
PDF
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
2021 · Manal F. Abdelmalek, Edgar D. Charles, et al. · Contemporary Clinical Trials · 64
PDF
LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
2022 · Benjamin E. Decato, Diana Julie Leeming, et al. · Respiratory Research · 55
PDF
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
2023 · Elizabeth A. Brown, Anne Minnich, et al. · JHEP Reports · 37
PDF
The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis
2021 · Grace Hyun J. Kim, Jonathan G. Goldin, et al. · Therapeutic Advances in Respiratory Disease · 31
PDF
The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement
2023 · David J. Donnelly, Joonyoung Kim, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 26
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study
2023 · Philip G Conaghan, Miroslawa Nowak, et al. · The Lancet Rheumatology · 26
Association between Polymorphisms of the IKZF3 Gene and Systemic Lupus Erythematosus in a Chinese Han Population
2014 · Xinze Cai, Ying Qiao, et al. · PLoS ONE · 26
PDF
Upregulation of miR-335 ameliorates myocardial ischemia reperfusion injury via targeting hypoxia inducible factor 1-alpha subunit inhibitor.
2018 · Nan Wu, Xiaowen Zhang, et al. · PubMed · 22
Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand 11 C-BMT-136088 for Lung Imaging in Rhesus Monkeys
2017 · Jean-Dominique Gallezot, Nabeel B. Nabulsi, et al. · Journal of Nuclear Medicine · 20
PDF
1,25(OH)2D3 inhibits high glucose-induced apoptosis and ROS production in human peritoneal mesothelial cells via the MAPK/P38 pathway
2016 · LINA YANG, LAN WU, et al. · Molecular Medicine Reports · 20
PDF
Zinc supplementation inhibits the high glucose‑induced EMT of peritoneal mesothelial cells by activating the Nrf2 antioxidant pathway
2019 · Lili Gao, Yi Fan, et al. · Molecular Medicine Reports · 15
PDF
Yes-Associated Protein 1 Inhibition Induces Immunogenic Cell Death and Synergizes With Radiation and PD-1 Blockade
2023 · Yuan Zhuang, Yuzi Wang, et al. · International Journal of Radiation Oncology*Biology*Physics · 13
Overexpression of Aiolos in Peripheral Blood Mononuclear Cell Subsets from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
2015 · Xinze Cai, Xudong Liu, et al. · Biochemical Genetics · 12
Expression and Polymorphisms of Lysosome-Associated Protein Transmembrane 5 (LAPTM5) in Patients with Systemic Lupus Erythematosus in a Chinese Population
2015 · Xinze Cai, Ying Qiao, et al. · Biochemical Genetics · 12
Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis
2022 · Mikkel Østergaard, Paul Bird, et al. · Lara D. Veeken · 10
PDF
Development, Characterization, and Radiation Dosimetry Studies of 18F-BMS-986229, a 18F-Labeled PD-L1 Macrocyclic Peptide PET Tracer
2023 · Joonyoung Kim, David J. Donnelly, et al. · Molecular Imaging and Biology · 9
PDF
Works count: 56
Citation count: 1,866
H-index: 19
I10-index: 24
Year
Topic
Type